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Abstract
The burden of liver disease continues to increase in the UK, with liver cirrhosis reported to
be the third most common cause of premature death. Iron overload, a condition that impacts
liver health, was traditionally associated with genetic disorders such as hereditary haemo-
chromatosis, however, it is now increasingly associated with obesity, type-2 diabetes and
non-alcoholic fatty liver disease. The aim of this study was to assess the prevalence of ele-
vated levels of liver iron within the UK Biobank imaging study in a cohort of 9108 individuals.
Magnetic resonance imaging (MRI) was undertaken at the UK Biobank imaging centre,
acquiring a multi-echo spoiled gradient-echo single-breath-hold MRI sequence from the
liver. All images were analysed for liver iron and fat (expressed as proton density fat fraction
or PDFF) content using LiverMultiScan. Liver iron was measured in 97.3% of the cohort.
The mean liver iron content was 1.32 ± 0.32 mg/g while the median was 1.25 mg/g (min:
0.85 max: 6.44 mg/g). Overall 4.82% of the population were defined as having elevated liver
iron, above commonly accepted 1.8 mg/g threshold based on biochemical iron measure-
ments in liver specimens obtained by biopsy. Further analysis using univariate models
showed elevated liver iron to be related to male sex (p<10−16, r2 = 0.008), increasing age
(p<10−16, r2 = 0.013), and red meat intake (p<10−16, r2 = 0.008). Elevated liver fat (>5.6%
PDFF) was associated with a slight increase in prevalence of elevated liver iron (4.4% vs
6.3%, p = 0.0007). This study shows that population studies including measurement of liver
iron concentration are feasible, which may in future be used to better inform patient stratifi-
cation and treatment.
Introduction
The burden of chronic liver disease and its impact on morbidity in terms of liver failure, fibro-
sis and end-stage cirrhosis and, ultimately, mortality is increasing, reportedly at much higher
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rates in the UK than other western European countries [1,2]. Whilst the aetiology of liver dis-
ease varies, common causes include viruses (e.g. Hepatitis C), autoimmune conditions, as well
as lifestyle related factors including obesity and alcohol. The consequence of an increasingly
obese population has a significant impact both on the prevalence and severity of non-alcoholic
fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as the progres-
sion of both Hepatitis C and alcohol related liver diseases [3, 4].
Iron overload is traditionally associated with genetic disorders such as hereditary haemo-
chromatosis (HH) or as a result of repeated blood transfusions. However elevated levels of
liver iron are now often associated with metabolic diseases including insulin resistance, type-2
diabetes and NAFLD [5–7]. This has been referred to as insulin resistance-associated hepatic
iron overload [8,9] or as it is now more commonly known dysmetabolic iron overload syn-
drome (DIOS). Unlike HH where liver iron concentrations are severely raised, with DIOS
mild increases in iron stores are more common [6]. It has been suggested that one third of
patients with NAFLD have DIOS [6], with others reporting even greater prevalence [7].
Irrespective of its causes, identifying individuals storing excess liver iron and assessing its
prevalence within the population is paramount since elevated liver iron is associated with the
development of fibrosis and cirrhosis, and thought to be involved in the progression from
fibrosis to hepatocellular carcinoma [10]. There is however ongoing debate as to whether this
progression is driven by the mild to moderate levels of liver iron typically observed in subjects
with NAFLD or the high levels of serum ferritin that are often observed [11]. To fully under-
stand the health implications of elevated levels of liver iron content, an assessment of its preva-
lence within the population is necessary as well as developing population appropriate methods
for its measurement which will allow early identification and monitoring of response to inter-
ventions, prior to the onset of organ failure.
Liver biopsy is the gold standard for assessment of liver iron, with a normal levels of liver
iron reported as<1.8 mg/g dry weight [12,13]. However, liver biopsy is not clinically recom-
mended except in cases where advanced fibrosis is suspected [14,15]. The need to regularly
measure liver iron content commonly relies on indirect blood-based biomarkers such as
serum ferritin. However, ferritin levels can be influenced by liver damage and inflammation,
and in many cases do not correlate well with liver iron stores [16]. This has necessitated the
development of robust non-invasive techniques for the measurement of liver iron based on
magnetic resonance imaging (MRI) [17,18].
MRI measurements of liver iron are based on the principle that the rate of MR signal decay
is influenced by the levels of iron in the tissue; more iron present results in a faster signal
decay. Multiple calibration studies have been published, comparing measurements of liver
iron by MRI and tissue biopsy, establishing MRI as a suitable method for the assessment of
liver iron in both healthy and iron-overload subjects [17,19–24]. Despite numerous studies uti-
lising MRI to measure liver iron, these have generally been conducted in relatively small and
well defined patient populations. Few studies have characterised the distribution of liver iron
within the general population. In the present study, we describe the measurement of liver iron
in a population >9,000 individuals within the UK Biobank Cohort, and assess its distribution
in relation to age, sex, body habitus and liver fat content.
Patients and methods
Study design
The UK Biobank (UKB) imaging study is a large prospective study of people aged between 40–
69 years (at the time of initial recruitment in 2006–2010), with a planned 100,000 subjects to
be recruited from the wider 500,000-strong general UK Biobank Cohort. This study assesses
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the first 9108 subjects from the UKB imaging enhancement protocol, acquired between 2014
and 2016, with patient meta-data obtained through UK Biobank Access Application number
9914. The UK Biobank has approval from the North West Multi-Centre Research Ethics Com-
mittee (MREC), and obtained written informed consent from all participants prior to the
study.
We performed a cross-sectional study in UK Biobank (52.4% female, mean age 61.4 [44–
73] years, 96.7% white), to determine how liver iron varies according to sex, age, body mass
index (BMI) and liver fat.
Imaging protocol
Participants were scanned at the UK Biobank imaging centre in Cheadle (UK) using a Siemens
1.5T Magnetom Aera. A multi-echo spoiled gradient-echo single-breath-hold MRI sequence
was acquired as a single transverse slice captured through the centre of the liver superior to the
porta hepatis. This sequence is part of the LiverMultiScan protocol from Perspectum Diagnos-
tics (UK) which forms part of the UK Biobank abdominal imaging protocol [25,26].
Image analysis
The data was analysed using the LiverMultiScan Discover software by a team of trained ana-
lysts, blinded to any subject variables. Analysts selected three 15mm diameter circular regions
of interest (ROIs), to cover a representative sample of the liver parenchyma, avoiding vessels,
bile ducts and other organs. Mean T2�, liver iron, and PDFF were calculated. The repeatability
and reproducibility of the image analysis is described in the S1 Appendix.
Presentation of liver iron
There is little consensus within the literature regarding the best protocol for the measurement
of liver iron by MRI. Liver iron measures obtained by MRI are sometimes reported as T2�
and/or R2� or converted to iron in mg/g, utilising a variety of formulas (S1 Table) based on
regression analysis in studies where both MRI and biopsy data were available [17,19–23,27].
The impact on the final results arising from the use of these formulas can be seen in S2 Table.
In the present study values are presented as mg/g as described by Wood et al [19], with a cut-
off of<1.8 mg/g dry weight for healthy liver iron [12,13], which equates to a R2� cut-off of
62.7 sec-1. Wherever appropriate, T2� and R2� values are also shown (S2 Table).
Statistical methodology
Summary data are presented as means, medians and quartiles. Assessment of difference of
prevalence of elevated liver iron levels by stratified groups was completed using chi-squared
tests. Subjects were stratified into age (40–49, 50–59, 60–69 and 70–79 years) and BMI groups
(<20 kg/m2, 20–24.9 kg/m2 (normal), 25–29.9 kg/m2 (overweight), 30–34.9 kg/m2 (obese),
and>35 kg/m2 (very obese). Repeatability and reproducibility were assessed with intra-class
correlation (ICC) [28] and Bland-Altman analyses [29] (presented in S1 Appendix). Linear
models were fitted using R. Liver fat values were log transformed for the purposes of the mod-
els, since this transformation resulted in an improved fit, with more normal residuals. Categor-
ical variables were modelled as fixed effects. Iron values were capped at 3mg/g in plots but left
untransformed for all other analysis. For beef intake, the results were recoded to give groups
with sufficient numbers. The "2–4 times a week", "5–6 times a week", and "Once or more daily"
labels were combined into a single level of “More than once a week”. The "Do not know" and
"Prefer not to answer" levels were set to missing values. The remaining three levels, “Never”,
Liver iron in the UK Biobank
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"Less than once a week", and "Once a week", were left unchanged. Statistical analyses were
undertaken using Python 3.6 (Python Software) and R 3.4.4 (R Core Team) [30, 31].
Results
Liver iron was measured in 8865 (97.33%) of the 9108 MRI datasets available. Of the 243
(2.67%) cases not deemed of sufficient quality for analysis; 170 had artefacts, in 41 cases the
slice was incorrectly positioned and did not include usable liver, 15 could not be linked to their
metafiles and 10 were rejected during quality control processing due to missing or corrupted
files. A further 7 were rejected as their T2� values were below the limits of detection.
The demographics of the population included in the final analysis are presented in Table 1.
The mean and median liver iron for this cohort was 1.32 ± 0.32 mg/g and 1.25 mg/g (min:
0.85 max: 6.44 mg/g) respectively (Table 2). The distribution of liver iron within the popula-
tion is presented in Fig 1 (and also shown as a T2� distribution in S1 Fig). Overall 4.82% of the
population were defined as having elevated liver iron, above the commonly accepted 1.8mg/g
threshold [12, 13].
For a ‘reference’ population, defined as those individuals with BMI <25 kg/m2, and PDFF
<5%, the 95% range was 0.98–2.06 mg/g dry weight (this corresponds to a T2� range of 32.2–
13.6 ms, and a R2� range of 31.02–74.87 s-1). This population had a very similar average age
(61.37 years) to the whole cohort (61.10 years).
Table 1. General population statistics.






40–49 years 551 6.2
50–59 years 2651 29.9
60–69 years 4161 46.9
70–79 years 1093 12.3
Age not available 409 4.6
BMI (kg/m2)
<20 kg/m2 294 3.3
20–24.9 kg/m2 3189 36.0
25–29.9 kg/m2 3725 42.0
30–34.9 kg/m2 1222 13.8
>35 kg/m2 405 4.63







Other ethnicity 37 0.4
Ethnicity not available or subject preferred not to answer 82 0.9
https://doi.org/10.1371/journal.pone.0209340.t001
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Relationship with proton density fat fraction (PDFF)
Subjects were further stratified according to their liver fat content (PDFF), derived from MRI.
Overall 20.6% (1826) of participants had elevated PDFF (>5.6% [32]), There was a weak but
significant relationship between liver iron and log(PDFF) (r2 = 0.0496, p<10−16, Spearman’s.
r2 = 0.0279 Pearson’s, p<10−16), as shown in Fig 2. The estimated regression coefficient was
0.0595 mg/g/log(%), indicating that a doubling of liver fat corresponds, on average to an
increase of 0.0412 mg/g liver iron. This means that an individual with a PDFF of 1% and
another with a PDFF of 20% (roughly the extremes of the data) would have an average differ-
ence in liver iron content of 0.18mg/g.
Age and sex
Age was positively correlated with liver iron (p<10−16, r2 = 0.013), increasing 0.00512mg/g/
year (Fig 3). Males had, on average, 0.0586 mg/g more liver iron than females (p< 10−16, r2 =
0.008). Prevalence of elevated liver iron content was significantly more common in male com-
pared with female subjects (6.38% vs 3.4%, p<0.0001).
Relationship with body mass index
The impact of BMI on liver iron was also investigated; in this cohort 39.3% of the population
had a normal BMI, 42.0% were overweight and 18.4% were categorised as obese. There was a
small yet significant correlation between BMI and liver iron (r = 0.05, P<0.0001). The varia-
tion of liver iron against BMI is shown in Fig 4.
Ethnicity
While the cohort was predominantly Caucasian, (n = 8512) there were some Asian (n = 107),
Black (n = 51) and mixed-race individuals represented to enable preliminary analysis. This
showed a statistically significant difference (p<0.05) in liver iron between Caucasian (median
1.32 mg/g, range 1.14–1.41 mg/g) and Asian (median 1.26 mg/g, range 1.09–1.33 mg/g) sub-
jects, with no significant differences between the other ethnic groups.
Diet
There were significant differences in liver iron in relation to self-reported frequency of beef
intake. A fixed-effects model relating liver iron to this variable (recoded into four groups),
with the “Never” group as the baseline. The three other groups, “less than once a week”, “once
a week”, and “more than once a week”, had significantly more iron (p< 10−16 in all cases),
with 0.080, 0.108 and 0.122 mg/g higher liver iron respectively.
Table 2. Summary statistics for liver iron.








All data expressed as mg/g dry weight
https://doi.org/10.1371/journal.pone.0209340.t002
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Multivariate analysis
Age, sex, BMI, liver fat, and beef intake were used to create a combined model (S3 Table).
Interaction terms were included in the initial model fit, and then backward selection was used
Fig 1. Distribution of liver iron concentration (liver iron) within the UK Biobank population. Median value (1.25
mg/g) shown in red, mean (1.32 mg/g) in blue. There were 52 individuals with liver iron> 3mg/g, who are not shown
in this plot.
https://doi.org/10.1371/journal.pone.0209340.g001
Fig 2. Correlation of liver iron concentration and liver fat (MRI proton density fat fraction) in the UK Biobank
population.
https://doi.org/10.1371/journal.pone.0209340.g002
Liver iron in the UK Biobank
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to build the final model. In the final model, no interaction term was included, but each of age,
sex, BMI, log(PDFF), and beef intake were included. These were all found to be significantly
correlated (p< 10−7 in all cases). The coefficients from the model are shown in S3 Table. The
r2 for the model was 0.053. In the multivariate model, the coefficient for log(PDFF) was larger
than the univariate fit, but all other variables, except BMI, had lower coefficients in the
Fig 3. Correlation of liver iron concentration (mg/g dry weight) with age. Iron values above 3mg/g have been
capped to 3mg/g in the plot, but not as part of the linear fit. Dashed black line shows line of best fit in univariate linear
model.
https://doi.org/10.1371/journal.pone.0209340.g003
Fig 4. Graph showing distribution of BMI (kg/m2) in the UK Biobank population against liver iron (mg/g). Iron
values above 3mg/g have been capped to 3mg/g in the plot, but not as part of the linear fit. Dashed black line shows line
of best fit in univariate linear model.
https://doi.org/10.1371/journal.pone.0209340.g004
Liver iron in the UK Biobank
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multivariate model than in their respective univariate models. The BMI coefficient was
changed in sign with respect to the univariate model.
Discussion
The findings from this cross-sectional study into liver iron concentration in the UK Biobank
revealed that 4.82% of the subjects have elevated liver iron (>1.8 mg/g) and that age, sex, eth-
nicity, dietary intake of beef, BMI, and liver fat, had a significant impact.
The use of MRI based methodology to assess liver iron has enabled measurement in popula-
tions where biopsy may not have been appropriate. Whilst previous studies of liver iron have
generally focussed on small well-defined patient cohorts, there has recently been a similar pop-
ulation based study of liver iron in a German cohort (n = 2561) [33]. That study reported a
prevalence of elevated levels of liver iron of 17.4%, considerably higher than that reported in
the present study (<5%). The reason(s) underlying this difference are unclear but may relate
to the nature of the cohort under study. For example, prevalence of fatty liver disease within
the UK Biobank population was lower (20%) [26], than that reported by Kuhn et al (42.2%)
[33]. Given that in the present study we observed a higher proportion of elevated liver iron lev-
els in subjects with high PDFF, a far greater prevalence of elevated liver iron would also be
expected within the German cohort. However methodological differences in MR acquisition
and analysis, as well as the thresholds used for defining elevated levels of liver iron cannot be
discounted, as they could potentially contribute significantly to these differences. Kuhn’s study
reports a considerably lower median R2� (34.4s-1) and hence lower median liver iron, than
measured in our study (41.4 s-1). Moreover, reanalysis of our dataset using their stated cut-off
for elevated levels of liver iron, defined as R2�>41 sec-1 [34], would suggest that 51.5% of the
subjects in the UK Biobank would be deemed as having elevated levels of liver iron. Interest-
ingly, others have suggested a quite different cut-off for the normal R2� threshold, (see S4
Table for a summary of this data). Applying 57 s-1 cut-off suggested for multi-echo Dixon
sequences gives an UKBB prevalence of elevated liver iron levels of 7.5% [17]. Using 65 s-1 as
suggested by Paisant et al [27] would give a prevalence of elevated levels of liver iron within the
UK Biobank of 4.2%.
Moreover, using the <70 s-1 suggested by Henninger et al [20] would result in a prevalence
of elevated levels of liver iron of 3.0%. However, sequence dependence for cut-offs are known,
with 3D multi-echo Dixon sequences showing lower R2� values than 2D ME GRE sequences
[17]. Clearly choice of threshold to define elevated levels of liver iron will have considerable
impact on reported prevalence in population studies. Whilst these published thresholds have
been determined from extensive calibration studies combining MRI and biopsy data, many
are still dependent on several factors including choice of sequence, field strength and cohort.
Our overall finding of a prevalence of elevated levels of liver iron of just under 5%, based on
biopsy related cut-off, are in line with previously published studies of explant pathology
reports which found mildly elevated levels of liver iron in 5.6% of patients studied [35].
Correlations were observed between liver iron and several variables tested here. The effect
sizes were consistent between the univariate models and the combined model, except for the
BMI effect. The r2 was 0.05, indicating that these variables only explain a small amount of the
population variability, so it is likely that there are more drivers of liver iron concentration than
those discussed here. It is possible that the factors we have investigated in this model may be
surrogates for factors that affecting iron absorption or liver iron deposition and not causative
factors, further longitudinal and/or interventional studies will be required to understand this
further. The change in sign of the BMI effect between the univariate and combined models, is
Liver iron in the UK Biobank
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likely a result of the linear regression using correlated variables (BMI correlates with log
(PDFF), r2 = 0.31), and the resulting impact of this on the effect estimates of the linear model.
In the present study we report that liver iron increased significantly with age; 0.005 mg/g/
year in the univariate model, and 0.004 mg/g/year in the multivariate model. We did not
observe a different age-related trend in the male and female participants. An age-related
increase in liver iron has previously been reported [33], the hepatic iron index is based on the
concept that liver iron increases with age in HH [13]. Some of these have suggested that liver
iron increases until the age of 50 years and then declines [34, 36]. However there have also
been conflicting studies that have reported no age association between liver iron and HH [37,
38]. Further work may be necessary to fully understand this association, however there are rel-
atively few individuals with diagnosed HH within the UKBiobank study; 123 in the overall
cohort of 500,000, equating to approximately two individuals within the imaging cohort
included in the present study. The very small numbers of HH individuals appears to support
the view that the aetiology of the elevated levels of liver iron observed within the UKBB cohort
is more likely associated with DIOS, undiagnosed HH, or other factors such as thalassemia.
Currently, it is unclear whether this relatively small increase in liver iron can be regarded as
clinically relevant. However, several studies have suggested a link between liver iron and devel-
opment of fibrosis in subjects with NAFLD, although the underlying mechanisms may depend
on whether the liver iron accumulation was hepatocellular or parenchymal [39, 40]. Conse-
quently, it may be that in subjects with NAFLD even relatively small increases in liver iron
may be significant and warrant further investigation.
Liver iron was significantly higher in male compared with female subjects in the UK Bio-
bank cohort, although in absolute terms this difference was small. Prevalence of elevated liver
iron was also significantly more common in male subjects compared with female subjects.
This confirms the findings of previous studies which have reported similar sex differences in
liver iron levels and prevalence of elevated levels of liver iron [33, 40]. This is further supported
by studies showing more frequent prevalence of DIOS in males [8]. It has been shown that
iron levels in females are general low until the menopause when they increase considerably
[41], one suggestion is the gradual increases in body iron storage that occurs throughout aging
in men are ameliorated by the effects of menstruation [42], although other studies suggest that
this change may be accounted for by changes in dietary habits [43].
Ethnicity appeared to have a small yet significant impact of liver iron levels, which were sig-
nificantly elevated in Caucasian compared with Asian subjects. Given the differences in the
median values are very small, this may not be clinically significant, however reports of hemo-
chromatosis within Asian populations are low [44], therefore the impact of ethnicity of liver
iron levels may warrant further investigation.
There was a very weak relationship between liver iron and BMI, with prevalence of elevated
liver iron levels being less common in subjects with a BMI less than 20 kg/m2. Relatively few
studies have explored the relationship between BMI and elevated liver iron levels and available
data are conflicting. Zheng et al reported a positive association between liver iron and BMI
[45]; however, this is at odds with the findings of Nelson et al who reported lower BMI to be
associated with increased liver iron [40]. These differences may be accounted for by the fact
that our cohort was comprised from relatively healthy subjects from the general population
whereas previous studies had a disease positive NASH cohort.
A relationship between self-reported frequency of beef consumption of liver iron was
observed. It is established that there is a significant relationship between red meat consump-
tion and serum ferritin levels [46], and that overfeeding animals with dietary iron causes an
increase in liver iron [47]. Furthermore, there is a positive association between red meat intake
and liver cancer and chronic liver disease [48, 49]. Although the results presented here are
Liver iron in the UK Biobank
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preliminary, the UK Biobank data will allow further investigation of the impact of other dietary
factors which have been suggested to have an influence on liver iron and liver health
outcomes.
Limitations
There are several limitations that may impact on the extrapolation of the data obtained from
this UK Biobank population to the wider population. It has been shown that the UK Biobank
population are somewhat ‘healthier’ that the general UK population, furthermore the age
range is limited and there is relatively little ethnic diversity [50].
A further limitation of the current study is the paucity of serum ferritin measurements.
Given their general use in assessing iron status in subjects with NAFLD and their potential to
add to differentiation between individuals with DIOS and other forms of iron overload [11],
they would have been a valuable addition to this population study. However, this marker has
not yet been made available by the UKBiobank. In future it is envisaged that blood and other
biomarker will be used in combination with the MR measurements described in this paper to
aid the development of less complex and less expensive non-invasive tools for liver iron
assessment.
MRI measurement of liver iron based on acquisition of T2� or R2�, whilst having the advan-
tage of being fast and non-invasive, can struggle to obtain reliable measurements in very high
levels of liver iron content, since the MR signal decays very rapidly. Ideally multi-echo
sequences with sufficient echoes, and a short initial echo time need to be employed, but logistic
and technical limitations do not make this approach feasible for “large data” studies.
A further confounding factor which may influence the accurate assessment of liver iron
relates to the presence of fat infiltration in the liver, since fat-water signal cancellation effects
[18] are a particular problem for the type of T2�-Dixon sequence employed in the present
study [18, 51, 52]. This issue may be overcome by the use of the IDEAL sequence [53], which
addresses these effects by separating out water and fat signals.
Values here are derived from ROIs placed by trained analysts. While more automated
approaches are in development, currently human interaction is required to determine appro-
priate parts of the image to use. However, intra- and inter-rater reliability is excellent for this
analysis, as demonstrated by the ICC and Bland-Altman analysis.
Conclusions
In this paper we show that population studies measuring liver iron are not only feasible, but
can now become part of the ever expanding “big data” consortium. As more data is released
from the UK Biobank, future studies on liver iron will enable more in-depth investigation on
gene-environment interaction, as well as the impact of various lifestyle factors. Moreover, it
will provide unique insights to better inform future patient stratification and treatments for
elevated liver iron levels. This study has been able to uniquely assess the combined burden of
fatty liver and elevated liver iron levels within the UK Biobank population. We have reported
that a significant proportion of this population has fatty liver (20.7%) and elevated liver iron
levels (4.8%); with 1.3% of the total population having both elevated levels of fat and iron. It
has been cautioned in recent years that the UK health system is not prepared for the current
liver disease epidemic, with the Lancet Commission for Liver Disease making a series of rec-
ommendations in its 2014 report [54]. The numbers of individuals with abnormal levels for
two key liver disease risk factors are significant, and potentially represent millions in the wider
population. Therefore both liver fat and iron are noteworthy within the liver field’s future
research priorities and following public health response.
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